Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
March 19, 2021RADNOR, Pa., March 19, 2021 (GLOBE NEWSWIRE) -- NeuroRx, Inc. announced the first patient in its P2/3 study of inhaled ZYESAMI™ in the treatment of moderate and severe COVID-19 (AVICOVID-2) was...
-
March 9, 2021Feasibility work underway to determine the compatibility of NeuroRx's ZYESAMI™ (aviptadil, synthetic VIP) as a dry powder formulation using TFF's Thin-Film Freezing technology
NeuroRx, Inc. and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) are announcing that the companies have entered into a feasibility and material transfer agreement (Feasibility Agreement). Under the...
-
February 23, 2021NeuroRx to File for Emergency Use Authorization in This Patient Population if Positive Results Continue to be Demonstrated at Day-60 Endpoint in Line with FDA's New Guidance
NeuroRx, Inc. announced today that the Phase 2b/3 trial* of ZYESAMI™ (aviptadil, previously RLF-100™) for the treatment of Respiratory Failure in critically ill patients with Covid-19 has...
-
February 9, 2021If Authorized for Use, ZYESAMI™ Would be First Treatment Specifically for Critically Ill Patients with Respiratory Failure
NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF; OTCQB: RLFTF) today reported preliminary results from the Phase 2b/3 trial of ZYESAMI™ (aviptadil, previously RLF-100) in patients...
-
February 9, 2021If Authorized for Use, ZYESAMI™ Would be First Treatment Specifically for Critically Ill Patients with Respiratory Failure
NeuroRx, Inc. today reported preliminary results from their Phase 2b/3 trial of ZYESAMI™ (aviptadil, previously RLF-100) performed in collaboration with Relief Therapeutics Holdings, AG...
Click here to view our corporate presentation or on the image below
 |
